The U.S. pharmaceutical industry seeks to alter Medicare drug price negotiation laws under Trump's return. China approves ...

China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...

which was cleared in China for TNBC in 2022. The approval means Kelun has brought its TROP2 ADC to market ahead of ...

The latest health news includes studies on medications for thyroid issues and breast cancer, the healthcare industry's ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

(RTTNews) - HUTCHMED (China) Limited (?HCM) announced that following the contract renewal with the China National Healthcare Security Administration ("NHSA"), the updated National Reimbursement Drug ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move ...

AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that ...

AstraZeneca said last week that its China chief, Leon Wang, was under investigation by authorities there, raising concerns about the stability of the company’s sales in the country, its second ...